title: Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns.
abstract: BACKGROUND
  In many countries, vaginal antifungal drugs have been released on over-the-counter (OTC) markets, yet little is known about women's management of their symptoms.
  
  
  OBJECTIVE
  The aim of this study was to judge the appropriateness of self-medication with vaginal antifungal drugs by examining utilization patterns and physicians' experiences of women's self-medication.
  
  
  METHODS
  An anonymous questionnaire survey was carried out in 20 pharmacies in Finland of women buying OTC vaginal antifungal drugs in 1997. Out of the 453 questionnaires distributed, 299 (66%) were returned. A survey of a random sample of gynaecologists (n = 169) and specialists in general practice (n = 288) was carried out in 1996. The response rate was 77%.
  
  
  RESULTS
  Nearly all women had used vaginal antifungal drugs previously, 49% during the previous 6 months. Most women did not report any difficulties with treatment, but 44% of women used the drug against recommendations. Half of the women had symptoms that are more likely to be related to infections other than Candida. Physicians had observed several disadvantages of self-treatment, with unnecessary use and use for the wrong indications being the most often reported. In all, 31% of gynaecologists and 16% of GPs reported that these adverse events had been clinically significant, with delay in the treatment of other infections being the most common problem.
  
  
  CONCLUSIONS
  The results raise concerns about inappropriate use and women's ability to self-diagnose correctly. Because vaginal antifungal drugs are likely to remain on OTC markets, two ways to address these concerns are for physicians and pharmacy personnel to provide spontaneous information and to have more informative advertisements on vaginal antifungal drugs.
authors.affiliation: Stakes (National Research and Development Centre for Welfare and Health), POB 220, 00531 Helsinki, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Sihvo
authors.forename: R
authors.initials: R
authors.lastname: Ahonen
authors.forename: H
authors.initials: H
authors.lastname: Mikander
authors.forename: E
authors.initials: E
authors.lastname: Hemminki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D002181:Candidiasis, Vulvovaginal / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004363:Drug Utilization; D005194:Family Practice / Q000706:statistics & numerical data; D005260:Female; D005387:Finland; D006176:Gynecology / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D004366:Nonprescription Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D010820:Physicians / Q000523:psychology*; D012651:Self Medication / Q000009:adverse effects / Q000379:methods* / Q000523:psychology / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
chemical_list: D000935:Antifungal Agents; D004366:Nonprescription Drugs